{"id":350476,"date":"2026-11-17T14:56:58","date_gmt":"2026-11-17T09:26:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350476"},"modified":"2026-11-17T14:56:58","modified_gmt":"2026-11-17T09:26:58","slug":"enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/","title":{"rendered":"3 Enterprise Software Company, Pharmaceuticals Maker and Engineering Consultancy Stocks With a Strong Future Roadmap: Newgen Software Technologies, Ipca Laboratories and Engineers India"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Newgen Software Technologies, Ipca Laboratories and Engineers India: ROE of 14.2% to 22.0% and FY22 to FY26 revenue CAGR of 7.9% to 19.4%. Prices as of 16 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>workflow software, drug and design stocks<\/strong> to watch are <strong>Newgen Software Technologies<\/strong>, <strong>Ipca Laboratories<\/strong> and <strong>Engineers India<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>14.2% to 22.0%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 7.9% to 19.4%. Engineers India has the highest return on equity at 22.0%, while Newgen Software Technologies has the fastest revenue growth at 19.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Workflow software, drug and design stocks offer a focused view of a sector where demand keeps widening. Newgen Software Technologies, Ipca Laboratories and Engineers India cover an enterprise software company, a pharmaceuticals maker and an engineering consultancy.<\/p>\n<p>This list covers three workflow software, drug and design stocks with complete current figures: Newgen Software Technologies, Ipca Laboratories and Engineers India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#What_Are_Workflow_Software_Drug_and_Design_Stocks\" title=\"What Are Workflow Software, Drug and Design Stocks?\">What Are Workflow Software, Drug and Design Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Workflow_Software_Drug_and_Design_Stocks_at_a_Glance\" title=\"Workflow Software, Drug and Design Stocks at a Glance\">Workflow Software, Drug and Design Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Why_Do_Workflow_Software_Drug_and_Design_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Workflow Software, Drug and Design Stocks Have a Strong Roadmap in India?\">Why Do Workflow Software, Drug and Design Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Why_Newgen_Software_Technologies_Features_Among_These_Workflow_Software_Drug_and_Design_Stocks\" title=\"Why Newgen Software Technologies Features Among These Workflow Software, Drug and Design Stocks\">Why Newgen Software Technologies Features Among These Workflow Software, Drug and Design Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Why_Ipca_Laboratories_Features_Among_These_Workflow_Software_Drug_and_Design_Stocks\" title=\"Why Ipca Laboratories Features Among These Workflow Software, Drug and Design Stocks\">Why Ipca Laboratories Features Among These Workflow Software, Drug and Design Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Why_Engineers_India_Features_Among_These_Workflow_Software_Drug_and_Design_Stocks\" title=\"Why Engineers India Features Among These Workflow Software, Drug and Design Stocks\">Why Engineers India Features Among These Workflow Software, Drug and Design Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Newgen_Software_Technologies_vs_Ipca_Laboratories_vs_Engineers_India_on_Key_Financials\" title=\"Newgen Software Technologies vs Ipca Laboratories vs Engineers India on Key Financials\">Newgen Software Technologies vs Ipca Laboratories vs Engineers India on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Key_Risks_to_Check_Before_Investing_in_Workflow_Software_Drug_and_Design_Stocks\" title=\"Key Risks to Check Before Investing in Workflow Software, Drug and Design Stocks\">Key Risks to Check Before Investing in Workflow Software, Drug and Design Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Final_Thoughts_on_Workflow_Software_Drug_and_Design_Stocks\" title=\"Final Thoughts on Workflow Software, Drug and Design Stocks\">Final Thoughts on Workflow Software, Drug and Design Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#What_are_workflow_software_drug_and_design_stocks\" title=\"What are workflow software, drug and design stocks?\">What are workflow software, drug and design stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Which_workflow_software_drug_and_design_stocks_are_covered_in_this_list\" title=\"Which workflow software, drug and design stocks are covered in this list?\">Which workflow software, drug and design stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Why_do_workflow_software_drug_and_design_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do workflow software, drug and design stocks have a strong future roadmap in India?\">Why do workflow software, drug and design stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#How_has_Newgen_Software_Technologies_performed_financially\" title=\"How has Newgen Software Technologies performed financially?\">How has Newgen Software Technologies performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#How_has_Ipca_Laboratories_performed_financially\" title=\"How has Ipca Laboratories performed financially?\">How has Ipca Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#How_has_Engineers_India_performed_financially\" title=\"How has Engineers India performed financially?\">How has Engineers India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#What_risks_should_investors_check_before_buying_workflow_software_drug_and_design_stocks\" title=\"What risks should investors check before buying workflow software, drug and design stocks?\">What risks should investors check before buying workflow software, drug and design stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy-stocks-roadmap-grassland-list\/#Is_this_list_of_workflow_software_drug_and_design_stocks_investment_advice\" title=\"Is this list of workflow software, drug and design stocks investment advice?\">Is this list of workflow software, drug and design stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Workflow_Software_Drug_and_Design_Stocks\"><\/span><strong>What Are Workflow Software, Drug and Design Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Workflow software, drug and design stocks<\/strong> are listed companies that build software that helps banks and governments manage documents and workflows, make medicines and active ingredients for India and global markets, and offer engineering design and project management for refineries and industry. Their earnings depend on software licences, medicine demand and project awards.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Workflow_Software_Drug_and_Design_Stocks_at_a_Glance\"><\/span><strong>Workflow Software, Drug and Design Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/newgen\/newgen-software-technologies-ltd-share-price-today\">Newgen Software Technologies<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">433.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,835<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ipcalab\/ipca-laboratories-ltd-share-price-today\">Ipca Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,865.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">46,050<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.10<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/enginersin\/engineers-india-ltd-share-price-today\">Engineers India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">312.05<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,096<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Ipca Laboratories and Engineers India trade at a <strong>P\/E<\/strong> below the industry P\/E, while Newgen Software Technologies trades above it, which reflects the growth the market already expects. Readers comparing workflow software, drug and design stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Workflow_Software_Drug_and_Design_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Workflow Software, Drug and Design Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Workflow software, drug and design stocks have a strong roadmap in India because rising use of automation software, steady demand for medicines and a long pipeline of energy and industrial projects keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Enterprise software.<\/strong> Offices move to digital workflows.<\/li>\n<li><strong>Medicines.<\/strong> Patients need reliable formulations.<\/li>\n<li><strong>Engineering consulting.<\/strong> Refineries need design and management.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Newgen_Software_Technologies_Features_Among_These_Workflow_Software_Drug_and_Design_Stocks\"><\/span><strong>Why Newgen Software Technologies Features Among These Workflow Software, Drug and Design Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the <strong>workflow software, drug and design stocks<\/strong> on this list, Newgen Software Technologies, based in Delhi, offers low-code platforms for content management, process automation and customer engagement to banks, insurers and governments.<\/p>\n<p>The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a <strong>market capitalisation<\/strong> of Rs 6,835 crore. The stock trades at a <strong>P\/E<\/strong> of 21.8, above the industry P\/E of 17.5.<\/p>\n<p>Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.<\/p>\n<p><strong>What to watch:<\/strong> Monitor deal wins in the banking sector and the growth of recurring revenue.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ipca_Laboratories_Features_Among_These_Workflow_Software_Drug_and_Design_Stocks\"><\/span><strong>Why Ipca Laboratories Features Among These Workflow Software, Drug and Design Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the workflow software, formulations and project consulting shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.<\/p>\n<p>Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%.<\/p>\n<p>In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Engineers_India_Features_Among_These_Workflow_Software_Drug_and_Design_Stocks\"><\/span><strong>Why Engineers India Features Among These Workflow Software, Drug and Design Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Engineers India is a public sector engineering consultancy and project company that provides design, project management and construction services to oil, gas, petrochemical, fertiliser and infrastructure clients.<\/p>\n<p>Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%.<\/p>\n<p>The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.<\/p>\n<p><strong>What to watch:<\/strong> Monitor order inflow from refinery and petrochemical projects and execution of existing mandates.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Newgen_Software_Technologies_vs_Ipca_Laboratories_vs_Engineers_India_on_Key_Financials\"><\/span><strong>Newgen Software Technologies vs Ipca Laboratories vs Engineers India on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three workflow software, drug and design stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Newgen Software Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">809<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,641<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">301<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ipca Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,896<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,821<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,191<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Engineers India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,043<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,123<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">692<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Engineers India posts the highest return on equity in this group at 22.0%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and Newgen Software Technologies shows the fastest revenue growth with a 19.4% compound annual rate. A useful habit with workflow software, drug and design stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Workflow_Software_Drug_and_Design_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Workflow Software, Drug and Design Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these <strong>workflow software, drug and design stocks<\/strong>, the main points are: Long-term workflow software, formulations and project consulting shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Government spending.<\/strong> Public project funding can shift between periods.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter workflow software, drug and design stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Workflow_Software_Drug_and_Design_Stocks\"><\/span><strong>Final Thoughts on Workflow Software, Drug and Design Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Workflow software, drug and design stocks reward patient research into demand, execution and financial strength. Newgen Software Technologies, Ipca Laboratories and Engineers India each have a clear plan to grow. Based on the 16 November 2026 close, Newgen Software Technologies trades at Rs 433.3, Ipca Laboratories at Rs 1,865.5 and Engineers India at Rs 312.05. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these <strong>workflow software, drug and design stocks<\/strong> to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track workflow software, drug and design stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_workflow_software_drug_and_design_stocks\"><\/span><strong>What are workflow software, drug and design stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Workflow software, drug and design stocks are listed companies that build software that helps banks and governments manage documents and workflows, make medicines and active ingredients for India and global markets, and offer engineering design and project management for refineries and industry. Their earnings depend on software licences, medicine demand and project awards. This list looks at three of them, Newgen Software Technologies, Ipca Laboratories and Engineers India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_workflow_software_drug_and_design_stocks_are_covered_in_this_list\"><\/span><strong>Which workflow software, drug and design stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Newgen Software Technologies, Ipca Laboratories and Engineers India. Based on the 16 November 2026 close, Newgen Software Technologies traded at Rs 433.3, Ipca Laboratories at Rs 1,865.5 and Engineers India at Rs 312.05. Their return on equity ranges from <strong>14.2% to 22.0%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 7.9% to 19.4%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_workflow_software_drug_and_design_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do workflow software, drug and design stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Workflow software, drug and design stocks have a strong roadmap in India because rising use of automation software, steady demand for medicines and a long pipeline of energy and industrial projects keep widening the market for these companies. The main drivers are as follows. Enterprise software. Offices move to digital workflows. Medicines. Patients need reliable formulations. Engineering consulting. Refineries need design and management. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Newgen_Software_Technologies_performed_financially\"><\/span><strong>How has Newgen Software Technologies performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P\/E of 21.8, above the industry P\/E of 17.5. Looking ahead, digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ipca_Laboratories_performed_financially\"><\/span><strong>How has Ipca Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Engineers_India_performed_financially\"><\/span><strong>How has Engineers India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_workflow_software_drug_and_design_stocks\"><\/span><strong>What risks should investors check before buying workflow software, drug and design stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying <strong>workflow software, drug and design stocks<\/strong>. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Government spending. Public project funding can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_workflow_software_drug_and_design_stocks_investment_advice\"><\/span><strong>Is this list of workflow software, drug and design stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are workflow software, drug and design stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Workflow software, drug and design stocks are listed companies that build software that helps banks and governments manage documents and workflows, make medicines and active ingredients for India and global markets, and offer engineering design and project management for refineries and industry. Their earnings depend on software licences, medicine demand and project awards. This list looks at three of them, Newgen Software Technologies, Ipca Laboratories and Engineers India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which workflow software, drug and design stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Newgen Software Technologies, Ipca Laboratories and Engineers India. Based on the 16 November 2026 close, Newgen Software Technologies traded at Rs 433.3, Ipca Laboratories at Rs 1,865.5 and Engineers India at Rs 312.05. Their return on equity ranges from 14.2% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 19.4%.\"}},{\"@type\":\"Question\",\"name\":\"Why do workflow software, drug and design stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Workflow software, drug and design stocks have a strong roadmap in India because rising use of automation software, steady demand for medicines and a long pipeline of energy and industrial projects keep widening the market for these companies. The main drivers are as follows. Enterprise software. Offices move to digital workflows. Medicines. Patients need reliable formulations. Engineering consulting. Refineries need design and management. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Newgen Software Technologies performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P\/E of 21.8, above the industry P\/E of 17.5. Looking ahead, digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.\"}},{\"@type\":\"Question\",\"name\":\"How has Ipca Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.\"}},{\"@type\":\"Question\",\"name\":\"How has Engineers India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying workflow software, drug and design stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying workflow software, drug and design stocks. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Government spending. Public project funding can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of workflow software, drug and design stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Workflow Software, Drug and Design Stocks with a strong future roadmap: Newgen Software Technologies, Ipca Laboratories and Engineers India. Compare price, valuation, return on equity and revenue growth as of 16 November 2026.<\/p>\n","protected":false},"author":28,"featured_media":350474,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,25082,25079,5971,25080,13964,13945,25081,17776],"class_list":["post-350476","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-branded-drugs-and-refinery-design-stocks","tag-drug-and-design-stocks","tag-engineers-india","tag-formulations-and-project-consulting-shares","tag-ipca-laboratories","tag-newgen-software-technologies","tag-process-automation","tag-workflow-software"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350474"],"rank_math_title":["Software, Pharma and Engineering Consulting Stocks"],"rank_math_description":["Compare 3 workflow software, drug and design stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 16 Nov 2026."],"rank_math_focus_keyword":["workflow software, drug and design stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-enterprise-software-company-pharmaceuticals-maker-and-engineering-consultancy.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350476"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350476\/revisions"}],"predecessor-version":[{"id":350479,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350476\/revisions\/350479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350474"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}